Perspective. Evangelos Kotzagiorgis from the EMA discussed the European Regulatory Perspective on dissolution testing. In the afternoon, Johannes Krämer returned with a talk on "Examination of Level B Correlations with a BCS Class 2 Immediate-Release Formulation." He presented a case study using multisource propafenon film-coated tablets where the use of level B correlation of mean times provided an IVIVC. Nikoletta Fotaki discussed "From Dissolution to BA/BE Studies." She gave case studies where modeling and appropriate in vivo data led to successful development of IVIVCs. The workshop ended with Senka Radošević from Pliva speaking on "Importance of Study Design and Metrics for the Proof of Bioequivalence." She discussed how advancements in methods for IVIVC and predictions can provide essential tools to accelerate development of generic drugs. In the case when in vitro behavior is not a key to in vivo response, it is possible to compensate by planning the most suitable study design and metrics to be utilized for the demonstration of equivalence. Vivian Gray closed the workshop with remarks of thanks to the Croatian organizers and speakers and appreciation for the fine hospitality shown to the Focus Group speakers. She also thanked Maja Jakševac Mikša for the tour of the Croatian Pharmaceutical Society building.
There were about 80 attendees from five countries: Croatia, Serbia, Slovenia, Montenegro, and Bosnia and Herzegovina.
